Carly Forster

In a research report issued this morning, Cowen Phil Nadeau reiterated an Outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), with a price target of $45, following the news that the FDA had cancelled its upcoming ADCOM meeting for the company’s Hepatitis-B vaccine, sending shares down nearly 32% on Friday.

Since Apple Inc. (AAPL) became the highest valued company in the world with a $741.16 million market cap, analysts and investors have been following the company’s every move. This week, it looks like reports have focused on the release of the iPhone 6 series and Apple Watch. After the huge success of the launch of the iPhone 6 and iPhone 6 Plus, Apple fans have been speculating when Apple will release the iPhone 6s.

Apple (NASDAQ: AAPL) finally released its highly anticipated Apple Watch for presale on April 10th and sold out of all models in 6 hours. The Apple Watch will initially be available in the United States, Canada, China, France, Germany, Australia, Hong Kong, Japan, and the United Kingdom. The different models of the Apple Watch will retail between $349 for the sport watch and $10,000 for the top-of-the-line watch.